Gilead stops trial of cancer drug that was central to $4.9 billion deal

The drug is part of Gilead's diversification strategy beyond HIV and hepatitis.

Source: bizjournals.com Health Care:Pharmaceuticals headlines - July 24, 2023 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news